logo-loader

Redx Pharma's chief scientific officer talks grant funding for its fibrosis project

Published: 01:50 20 Nov 2019 AEDT

Redx Pharma PLC's (LON:REDX) chief scientific officer Dr Richard Armer speaks to Proactive London's Andrew Scott after announcing they'd won grant funding for their latest project.

They're collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the discovery of new treatments and will focus on potential new drugs for idiopathic pulmonary fibrosis (IPF), a life-threatening fibrotic lung condition.

New Redx CEO bringing leadership and skills to 'capitalise on its great science'

Lisa Anson, the new chief executive at Redx Pharma Plc (LON:REDX), sat down with Proactive's Andrew Scott just weeks after taking on the new role. Anson was the president of AstraZeneca PLC’s (LON:AZN) UK division immediately prior to joining, while she's also held various other senior...

on 19/7/18